Medaimun GmbH
- Address
- lock Available on a paid plan
Medaimun GmbH - Food Allergy Research Center
Medaimun GmbH is a specialized clinical research facility focused on advancing therapeutic solutions for patients with food allergies. The center concentrates on evaluating innovative immunological treatments designed to improve safety and long-term outcomes for individuals suffering from allergic reactions to food.
- Long-term safety and tolerability studies of novel biologic therapies
- Extension trials for immunomodulatory agents in food allergy management
- Clinical evaluation of ligelizumab and other anti-IgE therapeutic approaches
Through comprehensive extension studies, Medaimun GmbH plays a crucial role in establishing the long-term safety profiles of emerging treatments in allergic disease management. The center's research contributes valuable data on sustained tolerability and efficacy of biologic interventions, helping to transform the therapeutic landscape for patients with food allergies who require ongoing immunological support.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 therapeutic areas and 15 of 58 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 55 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 4 by active trials.
lock +3 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB3trials
lock +4 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Medaimun GmbH
lock Showing 1 of 16 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 52-Week Randomized Double-Blind Trial Comparing CHF5993 (Beclometasone Dipropionate, Formoterol Fumarate, Glycopyrronium Bromide) to Fluticasone Propionate/Salmeterol in Adolescents with Uncontrolled Asthma | Chiesi Farmaceutici S.p.A. | Phase III | Not Yet Recruiting | — | — |
IMP list
lock Showing 1 of 58 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Fluticasone Propionate | 5 | Unknown | 2024-06-04 | 2026-06-01 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.